Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Commvault Systems Inc (CVLT) vs Mesoblast Limited (MESO) Price & Performance

Commvault Systems IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Commvault Systems Inc vs Mesoblast Limited — how do they compare? Commvault Systems Inc trades at $151.43 (market cap $6.25B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Commvault Systems Inc is far larger — about 3.6× Mesoblast Limited's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Mesoblast Limited for 14 Days on average.

CVLTMESO
Market Cap
$6.25B$1.75B
Volume
632,727239,027
Sector
TechnologyHealth
52-Week High
$176.52$20.96
52-Week Low
$75.18$13.19
Typical Hold Time
17 Days14 Days
Enterprise Value
$6.24B$1.83B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Commvault Systems Inc

Commvault Systems (CVLT) trades at $150.28, down 3.03% on the day, but maintains a bullish technical outlook with strong institutional support. The company shows robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 81.09% gross margins and 32.77% ROE. Recent business developments include achieving AWS Data Competency and expanding FedRAMP High authorized services, positioning the company for continued growth in the cybersecurity resilience market.

CVLT presents a compelling growth story with strong fundamentals and positive analyst sentiment, though elevated valuation ratios (P/E 96.73, P/B 120.15) suggest premium pricing. The primary investment opportunity lies in the company's leadership in AI-era resilience solutions, while risks include valuation sensitivity and competitive pressures in the enterprise software space. Wall Street maintains a bullish stance with 54.55% buy ratings and a $156.55 consensus price target.

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →